A new drug Xgeva (denosumab) ?has been found that can significantly delay the time it takes for prostate cancer to spread to bone, and to cause bone pain. Injections of?Xgeva delayed disease progression by 4.2 months compared with placebo injections.?
There is a 33% reduction in the risk of developing symptoms of bone metastases, mainly pain? has been evident. At a meeting of the American Urological Association a cumulative 4.6% of denosumab patients were diagnosed with osteonecrosis of the jaw.
Rates of osteonecrosis of the jaw in 1.1% at year one, 2.9% at year two and 4.2% at year three ? were seen in patients with advanced cancer.
Osteonecrosis of the jaw is generally readily manageable. This study shows?significantly delayed worsening of pain in prostate cancer patients.
Tags: advanced cancer, American Urological Association, cancer, cancer treatment, chemotherapy, delayed, disease, FDA, managing cancer, metastases, new drug, osteonecrosis, osteoporosis, pain, pain disorder, pain management, progression, prostate
Source: http://chemogan.com/blog/?p=20
westminster abbey e online buckingham palace pippa gabe carimi prince of wales windsor
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.